Paper Details

  1. Home
  2. Paper Details

[Treatment of pulmonary fibrosis. New substances and new interventions].

Author: BonellaF, CostabelU

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Idiopathic pulmonary fibrosis is a progressive lung disease with poor prognosis. While several drugs have shown no efficacy, pirfenidone is the first approved treatment for mild to moderate idiopathic pulmonary fibrosis. Pirfenidone slows lung function decline and reduces disease progression, but may cause gastrointestinal discomfort, skin reactions, and rarely, elevated liver enzymes.
Paper Details　
Original Abstract of the Article :
Idiopathic pulmonary fibrosis is a chronic progressive lung disease with poor prognosis. The IFIGENIA trial showed that antioxidative therapy with N-acetylcysteine versus placebo for patients under treatment with prednisone plus azathioprine significantly slowed the deterioration of pulmonary functi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00108-011-2926-0

データ提供：米国国立医学図書館（NLM）

Pulmonary Fibrosis: A Desert of Difficulty, Oasis of Hope

Imagine a vast desert landscape - that's what pulmonary fibrosis is like for those afflicted. It's a chronic, progressive lung disease, and the prognosis is not good. This research delves into the search for effective treatments, offering a glimmer of hope in this challenging landscape.

A Quest for Solutions

Researchers have been exploring various avenues to combat pulmonary fibrosis. While some promising therapies have shown significant improvement, others have fallen short. For instance, N-acetylcysteine, an antioxidant, has shown a significant slowing of pulmonary function deterioration. However, drugs like etanercept, interferon-γ, bosentan, ambrisentan, imatinib, and sildenafil did not yield the desired results.

Pirfenidone: A Beacon in the Desert

This research highlights a key breakthrough in the treatment of pulmonary fibrosis. Pirfenidone, an antifibrotic agent, has been approved in the European Union for patients with mild to moderate idiopathic pulmonary fibrosis. Its efficacy in slowing the decline in lung function and reducing the risk of disease progression offers a beacon of hope for individuals struggling with this debilitating disease.

Dr.Camel's Conclusion

This research explores the challenging world of pulmonary fibrosis, highlighting both the difficulties and the promising advancements in its treatment. It offers a glimmer of hope for patients, demonstrating that even in the face of adversity, there can be progress towards a better tomorrow.

Date :
  1. Date Completed 2012-05-23
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

22095049

DOI: Digital Object Identifier

10.1007/s00108-011-2926-0

SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.